Liminatus Pharma, Inc. Class A Common Stock (LIMN)
How it compares with the broader market is one of its lowest-scoring factors — price trend score is near the bottom of its range.
LIMN scores higher than 27% of the 1,101 tickers we compare it with (Health Care).
As of 10 October 2026, Liminatus Pharma, Inc. Class A Common Stock (LIMN) scores 29 out of 100 on the Market Census six-factor composite, which puts it at the Below average score level. The score is made from six named factors: price trend, strength vs the market, company finances, insider trades, market mood and recent momentum. It records what they read on 10 October 2026, and it is not investment advice.
Updated · scores usually change about once a day
Key statistics
Market fields as reported. An em-dash means we hold no value for this ticker — most of the universe has no daily price or volume read.
- Relative volume
- 0.63× 30-day average
- 52-week range
- 3.29 – 141.50
- Market cap
- $4.67M
- Earnings date
- 12 Nov 2026
- Volume
- 16,857
- Avg. volume (30d)
- 26,923
- Open
- 3.55
- Previous close
- 3.69
- Day's range (regular session)
- 3.55 – 3.81
The last trade can be an extended-hours trade, so it can sit outside the regular-session range.
Shown without a peer ranking — we hold no percentile for these yet, so there is nothing here to locate them against.
- Beta
- —
- P/E (TTM)
- —
- EPS (TTM)
- —
Score breakdown · six named factors
Each bar is one part of the score, from 0 to 100. Read what the score means.
What the score says about LIMN right now
Liminatus Pharma, Inc. Class A Common Stock (LIMN) currently scores 29/100 on the Market Census six-factor composite, at the Below average score level. LIMN is +1.90% on the day and -3.59% over five sessions as of the most recent tick. Below average sits a bit below the middle. More of LIMN's data reads poorly than well. The level is a "look before you act" flag. It is not advice. LIMN's strongest factor is recent momentum at 53/100 — a fairly good read on how the price has moved lately. The weakest factor is strength vs the market at 0/100 — well below average next to the wider market.
Generated from the six-factor breakdown above. Changes when the underlying scores do, usually about once a day. More on what the score means.
See LIMN in the scanner
This page is free to read with no account at all. Signing up takes an email and a password: a free account runs the scanner on the top 10 scored rows of any scan, keeps one saved screen, a 5-ticker watchlist, and opens 12 ticker detail pages a day. The card is what starts a 30-day Premium trial — $0 that day, then $19.99/month from day 30, cancel online any time before then — and that is what turns on every matching row instead of the first 10, alerts, the 200-ticker watchlist and recent insider buys (SEC Form 4).
Recent LIMN news
Latest headlines that name Liminatus Pharma, one per story, sourced from Market Census’s news feed (Polygon/Massive + Finnhub).
- Liminatus Pharma Regains Compliance With Nasdaq’s Minimum Bid Price RuleBenzinga
- Liminatus Pharma Engages Synex Consulting To Support Clinical Development Of IBC101, CD19xCD22 Bivalent CAR-T Cell Therapy CandidateBenzinga
- Liminatus Pharma Board Adopts Resolutions Approving Reverse Stock Split Of Its Common Stock At Ratio Of 1-For-50Benzinga
Saved snapshot; the news and prices on this page can be an hour old or more.
Similar setups in Health Care right now
Six health care tickers whose composite scores are closest to LIMN’s 29, all within 1 point.
Sorted by closeness to LIMN’s composite score within Health Care. Saved snapshot; can be an hour old or more. Run the full scanner →
Prices delayed about 15 minutes; scores usually change about once a day. Not investment advice — see risk disclosure.